EUVIMEDEUVIMED entdecken
Open Access

Asymptomatic Intracranial Artery Stenosis/Occlusion in Heterozygous Familial Hypercholesterolemia: Its Frequency and Implications for Cerebrovascular and Cardiovascular Events

Sayaka Funabashi iD, Yu Kataoka iD, Mika Hori iD, Masatsune Ogura iD, Takahito Doi iD, Yoshiaki Morita, Eri Kiyoshige iD, Kunihiro Nishimura iD, Teruo Noguchi iD, Mariko Harada-Shiba

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.123.033972 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Sayaka Funabashi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Suita Japan. Hauptthemen laut MEDLINE: Hyperlipoproteinemia Type II, Asymptomatic Diseases, Magnetic Resonance Angiography. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The atherogenic characteristics of heterozygous familial hypercholesterolemia (HeFH) increase the risk of premature atherosclerotic cardiovascular disease including not only coronary artery disease but ischemic stroke. Asymptomatic intracranial artery stenosis/occlusion (IASO) is a major cause of ischemic stroke, but it has not yet been fully characterized in patients with HeFH. Methods and Results This study analyzed 147 clinically diagnosed subjects with HeFH who underwent magnetic resonance imaging/magnetic resonance angiography imaging for evaluation of IASO (≥50% diameter stenosis). Major adverse cerebrovascular and cardiovascular events (cardiac death, ischemic stroke, and acute coronary syndrome) were compared in patients with HeFH with and without asymptomatic IASO. Asymptomatic IASO was observed in 13.6% of patients with HeFH. The untreated low‐density lipoprotein cholesterol level (240±95 versus 244±75 mg/dL; P =0.67) did not differ between the 2 groups. Despite the use of lipid‐lowering therapies (statin, P =0.71; high‐intensity statin, P =0.81; ezetimibe, P =0.33; proprotein convertase subxilisin/kexin type 9 inhibitor, P =0.39; low‐density lipoprotein apheresis, P =0.14), on‐treatment low‐density lipoprotein cholesterol level in patients with both HeFH and IASO was still suboptimally controlled (97±62 versus 105±50 mg/dL; P =0.17), accompanied by a higher triglyceride level (median, 109 versus 79 mg/dL; P =0.001). During the 12.4‐year observational period (interquartile range, 6.2–24.6 years), asymptomatic IASO exhibited a 4.04‐fold greater likelihood of experiencing a major adverse cardiovascular event (95% CI, 1.71–9.55; P =0.001) in patients with HeFH. This increased risk of a major adverse cardiovascular event was consistently observed in a multivariate Cox proportional hazards model adjusting clinical characteristics (hazard ratio, 4.32 [95% CI, 1.71–10.9]; P =0.002).

Conclusions

A total of 13.6% of Japanese subjects with HeFH presented with asymptomatic IASO. Despite lipid‐lowering therapies, patients with both HeFH and IASO more likely had elevated risk of cerebrovascular and cardiovascular events. Our findings highlight asymptomatic IASO as a phenotypic feature of HeFH‐related atherosclerosis, which ultimately affects future outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperlipoproteinemia Type IIAsymptomatic DiseasesMagnetic Resonance AngiographyHumansMaleFemaleMiddle AgedHeterozygoteAdultRisk FactorsRetrospective StudiesConstriction, PathologicIschemic StrokeAgedCholesterol, LDLJapan

Stichwörter der Autor:innen

heterozygous familial hypercholesterolemiaintracranial artery stenosis/occlusionoutcome

Substanzen

Cholesterol, LDL

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine National Cerebral and Cardiovascular Center Suita Japan.
  • Department of Cardiovascular Medicine Kyorin University Faculty of Medicine Mitaka Japan.
  • Department of Molecular Innovation in Lipidology, National Cerebral and Cardiovascular Center Research Institute Suita Japan.
  • Department of Endocrinology Research Institute of Environmental Medicine Nagoya University Nagoya Japan.
  • Department of Clinical Laboratory Technology, Faculty of Medical Science Juntendo University Urayasu Japan.
  • Department of Radiology National Cerebral and Cardiovascular Center Suita Japan.

ORCID-Profile: Sayaka Funabashi, Yu Kataoka, Mika Hori, Masatsune Ogura, Takahito Doi, Eri Kiyoshige, Kunihiro Nishimura, Teruo Noguchi

Zitieren

APA

Funabashi, S., Kataoka, Y., Hori, M., Ogura, M., Doi, T., Morita, Y., Kiyoshige, E., Nishimura, K., Noguchi, T., & Harada-Shiba, M. (2024). Asymptomatic Intracranial Artery Stenosis/Occlusion in Heterozygous Familial Hypercholesterolemia: Its Frequency and Implications for Cerebrovascular and Cardiovascular Events. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.033972

Vancouver

Funabashi S, Kataoka Y, Hori M, Ogura M, Doi T, Morita Y, et al. Asymptomatic Intracranial Artery Stenosis/Occlusion in Heterozygous Familial Hypercholesterolemia: Its Frequency and Implications for Cerebrovascular and Cardiovascular Events. Journal of the American Heart Association. 2024. doi:10.1161/jaha.123.033972

BibTeX
@article{Funabashi2024,
  author = {Funabashi, Sayaka and Kataoka, Yu and Hori, Mika and Ogura, Masatsune and Doi, Takahito and Morita, Yoshiaki and Kiyoshige, Eri and Nishimura, Kunihiro and Noguchi, Teruo and Harada-Shiba, Mariko},
  title = {Asymptomatic Intracranial Artery Stenosis/Occlusion in Heterozygous Familial Hypercholesterolemia: Its Frequency and Implications for Cerebrovascular and Cardiovascular Events},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.123.033972}
}
Kostenlos starten →